Biogen explores new options for Spinraza as competitive threats escalate
In 2016, Biogen’s Spinraza became the first therapy to receive marketing authorisation for SMA, a rare neurodegenerative disease that primarily affects children.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more